Targeting the EGF-family ligand EREG using antibody-drug conjugates or neutralizing antibodies offers tumor specificity, as EREG is highly expressed in colorectal and lung cancers with low expression in normal tissues.28 This evidence concerns the gene EREG and neoplasm.